(Q38016538)

27 August 2017

title

The sweet and bitter sides of galectins in melanoma progression (English)

1 reference

27 August 2017

Russell R Braeuer

1

1 reference

27 August 2017

Einav Shoshan

series ordinal

2

1 reference

27 August 2017

Takafumi Kamiya

series ordinal

3

1 reference

27 August 2017

Menashe Bar-Eli

series ordinal

4

1 reference

27 August 2017

publication date

12 July 2012

1 reference

Pigment Cell & Melanoma Research

27 August 2017

published in

1 reference

27 August 2017

volume

25

1 reference

27 August 2017

issue

5

1 reference

27 August 2017

page(s)

592-601

1 reference

Galectin-3 precipitates as a pentamer with synthetic multivalent carbohydrates and forms heterogeneous cross-linked complexes

27 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-148X.2012.01026.X

Reversing melanoma cross-resistance to BRAF and MEK inhibitors by co-targeting the AKT/mTOR pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-148X.2012.01026.X

Final version of 2009 AJCC melanoma staging and classification

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-148X.2012.01026.X

Tumor galectin-1 mediates tumor growth and metastasis through regulation of T-cell apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-148X.2012.01026.X

Serum galectin-2, -4, and -8 are greatly increased in colon and breast cancer patients and promote cancer cell adhesion to blood vascular endothelium

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-148X.2012.01026.X

The role of galectins in colorectal cancer progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-148X.2012.01026.X

The use of temozolomide for the treatment of malignant tumors: clinical evidence and molecular mechanisms of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-148X.2012.01026.X

Outcomes of patients with metastatic melanoma treated with molecularly targeted agents in phase I clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-148X.2012.01026.X

Glycosylation, galectins and cellular signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-148X.2012.01026.X

Galectin-1 research in T cell immunity: past, present and future

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-148X.2012.01026.X

Metabolic inhibition of galectin-1-binding carbohydrates accentuates antitumor immunity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-148X.2012.01026.X

A study of tumor progression: the precursor lesions of superficial spreading and nodular melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-148X.2012.01026.X

Inhibition of Wnt signaling by cucurbitacin B in breast cancer cells: reduction of Wnt-associated proteins and reduced translocation of galectin-3-mediated β-catenin to the nucleus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-148X.2012.01026.X

A galectin-3 ligand corrects the impaired function of human CD4 and CD8 tumor-infiltrating lymphocytes and favors tumor rejection in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-148X.2012.01026.X

Tumor targeting and SPECT imaging properties of an (111)In-labeled galectin-3 binding peptide in prostate carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-148X.2012.01026.X

When galectins recognize glycans: from biochemistry to physiology and back again

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-148X.2012.01026.X

Galectin-1 receptors in different cell types

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-148X.2012.01026.X

Galectins: matricellular glycan-binding proteins linking cell adhesion, migration, and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-148X.2012.01026.X

Critical determinants of metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-148X.2012.01026.X

Galectin-3 regulates integrin alpha2beta1-mediated adhesion to collagen-I and -IV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-148X.2012.01026.X

NG2 proteoglycan promotes endothelial cell motility and angiogenesis via engagement of galectin-3 and alpha3beta1 integrin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-148X.2012.01026.X

Failure at the effector phase: immune barriers at the level of the melanoma tumor microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-148X.2012.01026.X

Synthetic galectin-3 inhibitor increases metastatic cancer cell sensitivity to taxol-induced apoptosis in vitro and in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-148X.2012.01026.X

Melanoma biology and new targeted therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-148X.2012.01026.X

Frequencies of NRAS and BRAF mutations increase from the radial to the vertical growth phase in cutaneous melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-148X.2012.01026.X

SR proteins and galectins: what's in a name?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-148X.2012.01026.X

Possible role of galectin-9 in cell aggregation and apoptosis of human melanoma cell lines and its clinical significance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-148X.2012.01026.X

Altered melanoma cell surface glycosylation mediates organ specific adhesion and metastasis via lectin receptors on the lung vascular endothelium

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-148X.2012.01026.X

Galectin binding to Mgat5-modified N-glycans regulates fibronectin matrix remodeling in tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-148X.2012.01026.X

N-Glycans in cancer progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-148X.2012.01026.X

Galectin-1-mediated biochemical controls of melanoma and glioma aggressive behavior

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-148X.2012.01026.X

Regulation of gene expression in melanoma: new approaches for treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-148X.2012.01026.X

Galectin-3 Promotes Chronic Activation of K-Ras and Differentiation Block in Malignant Thyroid Carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-148X.2012.01026.X

Galectin-3 is an important mediator of VEGF- and bFGF-mediated angiogenic response

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-148X.2012.01026.X

Galectin-3 protein modulates cell surface expression and activation of vascular endothelial growth factor receptor 2 in human endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-148X.2012.01026.X

Galectin-1 knockdown increases sensitivity to temozolomide in a B16F10 mouse metastatic melanoma model

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-148X.2012.01026.X

Phosphorylation of galectin-3 contributes to malignant transformation of human epithelial cells via modulation of unique sets of genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-148X.2012.01026.X

Transcriptional control of the melanoma malignant phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-148X.2012.01026.X

Galectin-3 regulates MUC1 and EGFR cellular distribution and EGFR downstream pathways in pancreatic cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-148X.2012.01026.X

Expression profiling of Galectin-3-depleted melanoma cells reveals its major role in melanoma cell plasticity and vasculogenic mimicry

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-148X.2012.01026.X

Galectin-3 induces endothelial cell morphogenesis and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-148X.2012.01026.X

Cleavage of galectin-3 by matrix metalloproteases induces angiogenesis in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-148X.2012.01026.X

Association of galectin-1 and galectin-3 with Gemin4 in complexes containing the SMN protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-148X.2012.01026.X

Modulation of the lung colonization of B16-F1 melanoma cells by citrus pectin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-148X.2012.01026.X

Locally generated VGVAPG and VAPG elastin-derived peptides amplify melanoma invasion via the galectin-3 receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-148X.2012.01026.X

Conveying glycan information into T-cell homeostatic programs: a challenging role for galectin-1 in inflammatory and tumor microenvironments.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-148X.2012.01026.X

Immunotherapy of melanoma: a critical review of current concepts and future strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-148X.2012.01026.X

Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-148X.2012.01026.X

Targeted inhibition of galectin-1 gene expression in tumor cells results in heightened T cell-mediated rejection; A potential mechanism of tumor-immune privilege

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-148X.2012.01026.X

Mutational tuning of galectin-3 specificity and biological function

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-148X.2012.01026.X

Galectin-3 promotes lamellipodia formation in epithelial cells by interacting with complex N-glycans on alpha3beta1 integrin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-148X.2012.01026.X

Coordinated expression of galectin-3 and caveolin-1 in thyroid cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-148X.2012.01026.X

Galectin-3, a novel binding partner of beta-catenin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-148X.2012.01026.X

21 January 2018

Cancer statistics, 2012

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-148X.2012.01026.X

Galectin-3 mediates nuclear beta-catenin accumulation and Wnt signaling in human colon cancer cells by regulation of glycogen synthase kinase-3beta activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-148X.2012.01026.X

Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-148X.2012.01026.X

Galectin-3 and galectin-1 bind distinct cell surface glycoprotein receptors to induce T cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-148X.2012.01026.X

Glycoprotein 90K/MAC-2BP interacts with galectin-1 and mediates galectin-1-induced cell aggregation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-148X.2012.01026.X

Protein-glycan interactions in the control of innate and adaptive immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-148X.2012.01026.X

Evaluation of the prognostic significance of serum galectin-3 in American Joint Committee on Cancer stage III and stage IV melanoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-148X.2012.01026.X

Galectin-1 and immunotherapy for brain cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-148X.2012.01026.X

Galectin-3 increases the motility of mouse melanoma cells by regulating matrix metalloproteinase-1 expression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-148X.2012.01026.X

Galectin-3 phosphorylation is required for its anti-apoptotic function and cell cycle arrest

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-148X.2012.01026.X

Galectin-3 translocates to the perinuclear membranes and inhibits cytochrome c release from the mitochondria. A role for synexin in galectin-3 translocation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-148X.2012.01026.X

Peptides specific to the galectin-3 carbohydrate recognition domain inhibit metastasis-associated cancer cell adhesion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-148X.2012.01026.X

Galectin-3 expression correlates with apoptosis of tumor-associated lymphocytes in human melanoma biopsies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-148X.2012.01026.X

Galectin-3 Expression Is Associated with Tumor Progression and Pattern of Sun Exposure in Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-148X.2012.01026.X

10.1111/J.1755-148X.2012.01026.X

21 January 2018

Identifiers

DOI

1 reference

27 August 2017

1 reference